Hot on the heels of Accord BioPharma recently announcing a US filing for a Stelara biosimilar – as well as a settlement that will let it enter the market in May 2025 – Chrys Kokino, president of Accord US, talks about how the product fits into the firm’s wider biosimilars strategy in the first part of a two-part interview with Generics Bulletin.
Accord BioPharma recently set out its stall for competition with Stelara (ustekinumab) in the US, announcing a biosimilar filing with the US Food and Drug Administration as well as a settlement deal that would allow it to launch its version in May 2025.
Talking with Generics Bulletin in the wake of that announcement, Chrys Kokino, Accord’s US president, explained why being first to market wasn’t seen by Accord BioPharma as the key to success on ustekinumab, as well as
Eight more ANDA filers remain in play challenging patents shielding Esperion’s Nexletol (bempedoic acid) after Micro Labs deal out litigation via a settlement agreement.
Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.
Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.
